182 related articles for article (PubMed ID: 19353305)
1. Histochemical contributions to the binding mechanism of complement (CR1, CR2) receptors.
Baranyay F
Pathol Oncol Res; 2009 Dec; 15(4):639-44. PubMed ID: 19353305
[TBL] [Abstract][Full Text] [Related]
2. Ligand specificities of mouse complement receptor types 1 (CR1) and 2 (CR2) purified from spleen cells.
Pramoonjago P; Takeda J; Kim YU; Inoue K; Kinoshita T
Int Immunol; 1993 Apr; 5(4):337-43. PubMed ID: 7684250
[TBL] [Abstract][Full Text] [Related]
3. Evidence for three binding sites for C3 (hemolytically inactive), C3b and C3d on a CR2-positive Burkitt lymphoma-derived cell line (Raji).
Barile G; Di Renzo L; Lipari M; Frati L; Faggioni A
FEBS Lett; 1993 Jun; 324(3):319-24. PubMed ID: 8405374
[TBL] [Abstract][Full Text] [Related]
4. Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2.
Molina H; Kinoshita T; Webster CB; Holers VM
J Immunol; 1994 Jul; 153(2):789-95. PubMed ID: 8021513
[TBL] [Abstract][Full Text] [Related]
5. Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3.
Vik DP; Fearon DT
J Immunol; 1985 Apr; 134(4):2571-9. PubMed ID: 3156185
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.
Sarrias MR; Franchini S; Canziani G; Argyropoulos E; Moore WT; Sahu A; Lambris JD
J Immunol; 2001 Aug; 167(3):1490-9. PubMed ID: 11466369
[TBL] [Abstract][Full Text] [Related]
7. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
[TBL] [Abstract][Full Text] [Related]
8. Binding of CD 35, CD 21 and CD 11B monoclonal antibodies and EAC complexes to lymphocytes. A comparative histochemical study.
Baranyay F; Magyarlaki T
Acta Morphol Hung; 1991; 39(1):33-41. PubMed ID: 1684692
[TBL] [Abstract][Full Text] [Related]
9. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2.
Kalli KR; Ahearn JM; Fearon DT
J Immunol; 1991 Jul; 147(2):590-4. PubMed ID: 1830068
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the binding of C3S and C3F to complement receptors types 1, 2, and 3.
Bartók I; Walport MJ
J Immunol; 1995 May; 154(10):5367-75. PubMed ID: 7730637
[TBL] [Abstract][Full Text] [Related]
11. Enhanced binding of immune complexes processed by erythrocyte CR1 (CD 35) receptors to purified CR2 (CD 21) receptors from tonsillar mononuclear cells.
Rask R; Rasmussen JM; Jepsen HH; Svehag SE
APMIS; 1989 Apr; 97(4):374-80. PubMed ID: 2524204
[TBL] [Abstract][Full Text] [Related]
12. Detection of complement receptors 1 and 2 on mouse splenic B cells using flow cytometry.
Donius LR; Weis JH
Methods Mol Biol; 2014; 1100():305-10. PubMed ID: 24218269
[TBL] [Abstract][Full Text] [Related]
13. Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts.
Grattone ML; Villiers CL; Villiers MB; Drouet C; Marche PN
Immunology; 1999 Sep; 98(1):152-7. PubMed ID: 10469246
[TBL] [Abstract][Full Text] [Related]
14. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.
Guthridge JM; Young K; Gipson MG; Sarrias MR; Szakonyi G; Chen XS; Malaspina A; Donoghue E; James JA; Lambris JD; Moir SA; Perkins SJ; Holers VM
J Immunol; 2001 Nov; 167(10):5758-66. PubMed ID: 11698449
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).
Clemenza L; Isenman DE
J Immunol; 2000 Oct; 165(7):3839-48. PubMed ID: 11034390
[TBL] [Abstract][Full Text] [Related]
16. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.
Reynes M; Aubert JP; Cohen JH; Audouin J; Tricottet V; Diebold J; Kazatchkine MD
J Immunol; 1985 Oct; 135(4):2687-94. PubMed ID: 2411809
[TBL] [Abstract][Full Text] [Related]
17. Analysis of C3-receptor activity on human B-lymphocytes and isolation of the complement receptor type 2 (CR2).
Micklem KJ; Sim RB; Sim E
Biochem J; 1984 Nov; 224(1):75-86. PubMed ID: 6239618
[TBL] [Abstract][Full Text] [Related]
18. Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor.
Kinoshita T; Thyphronitis G; Tsokos GC; Finkelman FD; Hong K; Sakai H; Inoue K
Int Immunol; 1990; 2(7):651-9. PubMed ID: 1703784
[TBL] [Abstract][Full Text] [Related]
19. Isolation of avirulent clones of Candida albicans with reduced ability to recognize the CR2 ligand C3d.
Franzke S; Calderone RA; Schaller K
Infect Immun; 1993 Jun; 61(6):2662-9. PubMed ID: 8500905
[TBL] [Abstract][Full Text] [Related]
20. The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells.
Nielsen CH; Pedersen ML; Marquart HV; Prodinger WM; Leslie RG
Eur J Immunol; 2002 May; 32(5):1359-67. PubMed ID: 11981823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
